Actinic Keratosis – scripted patients only

Actinic Keratosis – scripted patients only

Back to top


Your Doctor has discussed the best option to treat you and has prescribed GLENTRIZTM cream to treat your Actinic Keratosis.1 GLENTRIZTM cream is simple to use.
Back to top


Condition Information Actinic Keratosis lesions (plural: Actinic Keratoses) are skin lesions that occur as a result of long-term exposure to Ultra Violet (UV) radiation from sun. Actinic Keratosis may appear as dry scaly patches or pink brown spots on sun-exposed skin. They indicate that some sun damage has occured and are important to treat because, in a small number of cases they can lead to a some types of skin cancer. Actinic Keratosis are very common in fair-skinned people and occur partly because of local effects that UV radiation can have on the imune system. GlentrizTM cream works with your body’s immune response to help clear these lesions.
  1. GLENTRIZTM should be applied prior to your normal bedtime.
  2. GLENTRIZTM cream needs to remain on your skin for 8 (6 – 10) hours
  3. During the 6 – 10 hours treatment period, showering or bathing should be avoided.
  4. Before applying GLENTRIZTM cream you should wash the treatment area with mild soap and water.
  5. Allow the area to dry thoroughly.
  6. Open the sachet and apply the cream as a thin layer and rub it onto the affected area until the cream is absorbed.
  7. Do not cover the affected area with a dressing
  8. After the 6 – 10 hours treatment period, GLENTRIZTM cream can be washed off with mild soap and water.
Back to top


GLENTRIZTM is a cream that you apply to your superficial BCC. GLENTRIZTM works by stimulating your own immune system to recognise and destroy the skin cancer. During treatment, your treated area of skin is likely to appear noticeably different from normal skin. This is a sign that GLENTRIZTM treatment is working. Actinic Keratosis Before and After Pictures in Charlotte, NC*
Back to top


You may experience local skin reactions at the site of treatment. Your skin may
  • Feel itchy
  • Look flaky or scaly
  • Feel crusty
  • Develop scabs
  • Look and feel slightly swollen, or even hard
If you are feeling any discomfort from the treatment, you can take a break from treatment for a few days until the reactions subside, then resume the application of GLENTRIZTM cream as prescribed by your doctor. The rest periods will not interfere with your treatment plan.
Contact your Doctor if you experience any sign or symptom at the application site that restricts or prohibits your daily activity, or makes application of the cream difficult.
Please Note: You need to minimise or avoid exposure to natural or artificial sunlight.
Back to top


Your Doctor will explain how often to use GLENTRIZTM cream.
  • You will need to apply GLENTRIZTM 3 times per week (example: Monday, Wednesday and Friday) prior to normal sleeping hours, and leave on the skin for approximately 8 hours.
  • Continue GLENTRIZTM treatment for 4 weeks.
  • After a 4-week treatment-free period your Doctor will assess the treated area to determine clearance of your Actinic Keratosis.
  • If any Actinic Keratosis persists in the treatment area your Doctor will recommend that you apply GLENTRIZTM 3 times per week for an additional 4 weeks (for a maximum total treatment duration of 8 weeks).
  • Your Doctor may want to see you about 8 weeks after starting treatment.
Back to top


Think about your lifestyle then mark on this chart which days will suit you best to apply your GLENTRIZTM cream. You can use this table to record each time you apply the treatment – this will help you keep to the treatment plan prescribed by your Doctor.

Medical References

  1. GLENTRIZTM Professional Information. January 2021.
  2. Rapini RP, Bolognia J, Jorizzo JL (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. pp. Chapter 108. ISBN 978-1-4160-2999-1.
  3. Prajapati V, Barankin B (May 2008). "Dermacase. Actinic keratosis". Canadian Family Physician. 54 (5): 691, 699. PMC 2377206. PMID 18474700
  4. Moy RL (January 2000). "Clinical presentation of actinic keratoses and squamous cell carcinoma". Journal of the American Academy of Dermatology. 42 (1 Pt 2): 8–10. doi:10.1067/mjd.2000.103343. PMID 10607350.
S4 GLENTRIZTM Cream 5 % w/w (Cream): Registration Number: 49/34/0556. Each 250 mg sachet contains 12,5 mg of imiquimod. For full prescribing information refer to the professional information approved by the South African Health Products Regulatory Authority. January 2021. Glenmark Pharmaceuticals South Africa (Pty) Ltd, 2nd Floor, Building D, Stoneridge Office Park, 8 Greenstone Place, Greenstone, Edenvale, Gauteng, 1609, Tel: +27 (0)11 564 3900 GLET22/06/2021

Content Disclaimer:
You understand and acknowledge that all users of the Dis-Chem website or app are responsible for their own medical care, treatment, and oversight. All of the content provided on the website, are for INFORMATIONAL PURPOSES ONLY and DOES NOT CONSTITUTE THE PROVIDING OF MEDICAL ADVICE and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment. The content is not intended to establish a standard of care to be followed by a user of the website. You understand and acknowledge that you should always seek the advice of your physician or other qualified health provider with any questions or concerns you may have regarding your health. You also understand and acknowledge that you should never disregard or delay seeking medical advice relating to treatment or standard of care because of information contained in or transmitted through the website. Medical information changes constantly. Therefore the information on this website or on the linked websites should not be considered current, complete or exhaustive, nor should you rely on such information to recommend a course of treatment for you or any other individual. Reliance on any information provided on this website or any linked websites is solely at your own risk.
Back to top